Format

Send to

Choose Destination
Immunol Invest. 2019 Jul;48(5):466-479. doi: 10.1080/08820139.2019.1566356. Epub 2019 Jan 28.

Prognostic Values of CD38+CD101+PD1+CD8+ T Cells in Pancreatic Cancer.

Author information

1
a Department of Pathophysiology , Third Military Medical University , Chongqing , PR China.
2
b Department of Cell Biology , Third Military Medical University , Chongqing , PR China.
3
c Institute of Hepatopancreatobiliary Surgery, Southwest Hospital , Third Military Medical University , Chongqing , PR China.
4
d Bellevue Christian High School , Bellevue , WA , USA.
5
e Department of Oncology and Southwest Cancer Center, Southwest Hospital , Third Military Medical University , Chongqing , PR China.

Abstract

Programmed death-1 (PD-1), a key immune checkpoint molecule, has been developed as an oncotherapy target for various carcinomas. However, treatment with anti-PD-1 elicited only a minimal effect in pancreatic ductal adenocarcinoma (PDAC). Subsequent studies revealed the existence of a subset of PD-1+ T cells coexpressing CD38 and CD101, representing a fixed dysfunctional subpopulation that are not able to be rescued by anti-PD-1 immunotherapy. However, whether this subpopulation of PD-1 expressing CD8+ T cells could be useful in predicting PDAC stage or prognosing survival is unknown. In this study, we used flow cytometry and immunofluorescence assay to analyze the expression of CD38 and CD101 in 183 clinical PDAC samples, including 84 of peripheral blood and 99 of surgical tissues. High coexpression of CD38/CD101 on peripheral PD-1+CD8+ T cells or tumor-infiltrating lymphocytes (TILs) was found to be most significantly correlated with Tumor/Node/Metastasis (T/N/M) classification and clinical stage, in contrast PD-1+CD8+ T cells could not correlate with T classification. CD38/CD101 co-repression on TILs also correlated with the poor survival in these PDAC patient samples. Our data suggest that CD38/CD101 might represent a more helpful biomarker than PD-1 alone for diagnosis and prognosis of PDAC.

KEYWORDS:

CD101; CD38; PD-1; Pancreatic ductal adenocarcinoma; prognosis

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center